Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT)
reduces prostate cancer (PCa) growth in virtually all patients, but response may be …

Medical imaging of the 3 most common genitourinary (GU) cancers—prostate
adenocarcinoma, renal cell carcinoma, and urothelial carcinoma of the bladder—has …

Recent advances in microfluidic approaches have enabled the efficient isolation and
detailed molecular characterization of circulating tumor cells (CTCs) in the peripheral blood …

Prostate cancer is unique compared to other major cancers due to the presence of multiple
primary malignant foci in the majority of patients at the time of diagnosis. Each malignant …

Background Slow-growing prostate cancer (PC) can be aggressive in a subset of cases.
Therefore, prognostic tools to guide clinical decision-making and avoid overtreatment of …

Molecular profiling already exerts a profound influence on biomedical research and disease
management. Microdissection technologies contribute to the molecular profiling of diseases …

Background Accurate local staging is critical for treatment planning and prognosis in
prostate cancer (PCa). Although multiparametric magnetic resonance imaging (mpMRI) has …

Next‐generation sequencing is making sequence‐based molecular pathology and
personalized oncology viable. We selected an individual initially diagnosed with …

Novel and minimally-invasive prostate cancer (PCa)-specific biomarkers are needed to
improve diagnosis and risk stratification. Here, we investigated the biomarker potential in …

Prevalent gene fusions involving regulatory sequences of the androgen receptor (AR)
regulated genes (primarily TMPRSS2) and protein coding sequences of nuclear …